Asrgl1 in endometrial cancer

A method of treatment of a subject having an endometrial cancer, comprising the steps of:

• a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
• b) comparing said sample value with a predetermined reference value;
• and
• if said sample value is lower than or equal to said reference value,
• c) treating said subject with an endometrial cancer treatment regimen.

A method for determining whether a mammalian subject having an endometrial cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of:

• a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
• b) comparing said sample value with a predetermined reference value;
• and
• if said sample value is higher than said reference value,
• c1) concluding that the subject belongs to the first group;
• and
• if said sample value is lower than or equal to said reference value,
• c2) concluding that the subject belongs to the second group.

A method for determining whether a first or a second number of lymph nodes shall be removed from a mammalian subject having an endometrial cancer, wherein the first number is higher than the second number, comprising the steps of:

• a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
• b) comparing said sample value with a predetermined reference value;
• and
• if said sample value is higher than said reference value,
• c1) removing the second number of lymph nodes;
• and
• if said sample value is lower than or equal to said reference value,
• c2) removing the first number of lymph nodes.